Nevertheless, comprehensive characterization through gene expression profiling, pathway enrichment analysis, and cell signatures provides robust evidence to support the distinct patterns identified between the KRAS-mutant RCC subtypes. The gene discussed is KRAS; the disease is renal cell carcinoma.